BC Innovations | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021. The C round syndicate includes Matrix...
BC Week In Review | Dec 15, 2017
Clinical News

Radius reports additional Phase I data for breast cancer candidate

Radius Health Inc. (NASDAQ:RDUS) reported additional data from the Phase I RAD1901-005 trial of elacestrant (RAD1901) in heavily pretreated, estrogen receptor-positive, HER2-negative patients with advanced breast cancer. Early next year, the company said it plans...
BC Extra | Dec 8, 2017
Clinical News

Radius rises on Phase I breast cancer readout

Radius Health Inc. (NASDAQ:RDUS) gained $4.19 (15%) to $31.60 after reporting data from the Phase I 005 trial of elacestrant (RAD1901) in heavily pretreated, estrogen receptor-positive, HER2-negative patients with advanced breast cancer. Early next year,...
BC Week In Review | Dec 9, 2016
Clinical News

RAD1901: Ph I RAD1901-005 data

Data from 19 evaluable heavily pretreated postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer in the safety expansion second part of the open-label, 4-part, U.S. Phase I RAD1901-005 trial showed that once-daily 400 mg...
BC Week In Review | Dec 9, 2016
Clinical News

RAD1901: Ph Ib RAD1901-106 data

Data from 3 postmenopausal women with estrogen receptor-positive, HER2-negative breast cancer who received ≤3 prior lines of endocrine therapy in the metastatic setting in the open-label, European Phase Ib RAD1901-106 trial showed that once-daily 400...
BC Extra | Dec 9, 2016
Clinical News

Radius slips after Phase I readouts for SERM program

Radius Health Inc. (NASDAQ:RDUS) lost $6.43 (12%) to $47.07 on Thursday after announcing early data from two Phase I trials of RAD1901 to treat estrogen receptor (ER)-positive breast cancer. In a safety expansion cohort of...
BC Week In Review | Feb 15, 2016
Company News

Radius Health, Novartis deal

The companies partnered to evaluate Radius’ RAD1901 in combination with either Novartis’ ribociclib ( LEE011 ) or the pharma’s alpelisib ( BYL719 ) in studies to treat breast cancer. The partners will share expenses and jointly own data. RAD1901,...
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Mar 30, 2015
Company News

Eisai Co. Ltd, Radius Health deal

Radius now has worldwide rights to develop and commercialize RAD1901 after receiving Japanese rights from Eisai. In 2006, the pharma granted Radius ex-Japanese rights to develop and commercialize selective estrogen receptor modulators (SERMs). Radius will...
BC Week In Review | Jun 28, 2010
Clinical News

RAD1901: Phase IIa data

In a double-blind, dose-ranging, Argentinian Phase IIa trial in 100 postmenopausal women, once-daily 10 mg oral RAD101 significantly reduced the frequency of moderate-to-severe hot flashes from baseline to week 4 by 77% vs. 54% for...
Items per page:
1 - 10 of 11